Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma

Abstract About 60% of patients with diffuse large B-cell lymphoma (DLBCL) may be cured by primary chemotherapy with an R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen. Most of the rest will die of the disease, mainly due to the occurrence of tumor drug resistance. Many efforts have been made to explain the molecular mechanisms of drug resistance in patients with cancer, including those with DLBCL. This exploratory study was designed to correlate the mRNA expression levels of candidate genes mainly involved in the doxorubicin pathway (ABCB1, GSTP1, TOPO2α, BCL2, PKCβII) with the outcome of 54 patients with DLBCL undergoing a dose-dense R-CHOP regimen. After multivariate analysis, high GSTP1 (p = 0.003) and TOPO2α (p = 0.02) gene expressions were associated with shorter overall survival and progression-free survival, respectively, suggesting that these genes may represent an unfavorable prognostic factor in the case of R-CHOP treatment. These biomarkers may be useful for selecting patients eligible for personalized chemotherapy after validation in an independent set.

[1]  David Cunningham,et al.  Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles , 2013, The Lancet.

[2]  Catherine Thieblemont,et al.  Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[3]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[4]  K. Dybkær,et al.  Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study , 2012, Leukemia.

[5]  W. Chan,et al.  Biological prognostic markers in diffuse large B-cell lymphoma. , 2012, Cancer control : journal of the Moffitt Cancer Center.

[6]  Jinfen Wang,et al.  Topo IIα gene alterations correlated with survival in patients with diffuse large B‐cell lymphoma , 2012, European journal of clinical investigation.

[7]  A. López-Guillermo,et al.  CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. , 2011, The Lancet. Oncology.

[8]  A. Bosi,et al.  Impact of Dose-Dense Immunochemotherapy on Prognosis of Germinal Center and Non Germinal Center Origin of Diffuse Large B Cell Lymphoma , 2011, Journal of chemotherapy.

[9]  Kai Fu,et al.  Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Byers,et al.  Impact of gene expression profiling in lymphoma diagnosis and prognosis , 2011, Histopathology.

[11]  Ash A. Alizadeh,et al.  Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. , 2010, Blood.

[12]  B. Coiffier,et al.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.

[13]  N. Pavlidis,et al.  High levels of topoisomerase IIα protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment , 2010, Leukemia & lymphoma.

[14]  M. Jerkeman,et al.  Prognostic impact of protein kinase C β II expression in R-CHOP-treated diffuse large B-cell lymphoma patients , 2010, Modern Pathology.

[15]  K. Opeskin,et al.  Protein Kinase C Beta II Expression in Diffuse Large B-Cell Lymphoma Predicts for Inferior Outcome of Anthracycline-Based Chemotherapy With And Without Rituximab , 2009 .

[16]  K. Opeskin,et al.  Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab , 2009, Leukemia & lymphoma.

[17]  A. Rosenwald,et al.  Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. , 2008, Blood.

[18]  T. Molina,et al.  The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab , 2008, Leukemia.

[19]  R. Tibshirani,et al.  Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. , 2007, Blood.

[20]  P. Bierman.  Natural history of follicular grade 3 non-Hodgkin's lymphoma , 2007, Current opinion in oncology.

[21]  T. Rebbeck,et al.  Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. , 2007, Blood.

[22]  S. Romano,et al.  PKC-beta II expression has prognostic impact in nodal diffuse large B-cell lymphoma , 2007, Modern Pathology.

[23]  R. Gascoyne,et al.  Clinical Trials and Observations , 2005 .

[24]  J. Briones,et al.  Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma , 2006, Annals of Hematology.

[25]  R. Gascoyne,et al.  Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. , 2006, Blood.

[26]  R. Gascoyne,et al.  Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  P. Gaulard,et al.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. Takayama,et al.  Plasma Glutathione S-Transferase P1-1 as a Prognostic Factor in Patients with Advanced Non-Hodgkin’s Lymphoma (Stages III and IV) , 2004, Clinical Cancer Research.

[29]  G. Brittinger,et al.  Topoisomerase IIα expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome , 2004, Leukemia.

[30]  Ash A. Alizadeh,et al.  Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.

[31]  D. Townsend,et al.  The role of glutathione-S-transferase in anti-cancer drug resistance , 2003, Oncogene.

[32]  P. Gaulard,et al.  Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). , 2003, Blood.

[33]  S. Koscielny,et al.  Prognostic value of GST-π expression in diffuse large B-cell lymphomas , 2003, Leukemia.

[34]  M. Teitell,et al.  PKC-β controls IκB kinase lipid raft recruitment and activation in response to BCR signaling , 2002, Nature Immunology.

[35]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[36]  C. Kittas,et al.  Evaluation of DNA topoisomerase IIα expression provides independent prognostic information in non‐Hodgkin's lymphomas , 2001, Histopathology.

[37]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[38]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  F. Gudat,et al.  Topoisomerase II alpha mRNA and tumour cell proliferation in non-Hodgkin's lymphoma. , 1997, Journal of clinical pathology.

[40]  E. Kleinerman,et al.  Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. , 1996, The Biochemical journal.

[41]  D C Linch,et al.  Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. , 1996, Blood.

[42]  J Hermans,et al.  Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[44]  I. Hickson,et al.  Cloning and characterization of the 5'-flanking region of the human topoisomerase II alpha gene. , 1992, The Journal of biological chemistry.

[45]  I. Lossos.  Diffuse large B cell lymphoma: from gene expression profiling to prediction of outcome. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[46]  S. Monti,et al.  in diff use large B cell lymphoma , 2006 .

[47]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[48]  M. Teitell,et al.  PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. , 2002, Nature immunology.

[49]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[50]  A. Tarakhovsky,et al.  Protein Kinase C (cid:2) Controls Nuclear Factor (cid:3) B Activation in B Cells Through Selective Regulation of the I (cid:3) B Kinase (cid:4) , 2002 .

[51]  R. Scott,et al.  Long-Term Results , 2001 .